Home / Expertise / Intellectual Property
padlock hanging from turquoise painted wooden doors

Intellectual Property

Poland

In today’s knowledge economy, your intellectual property plays a key role in obtaining a competitive advantage. A cohesive strategy, including both commercialisation and enforcement, will ensure you get maximum value from your IP. With specialist IP lawyers throughout Central and Eastern Europe (CEE), we have worked with some of the best-known brands, from banks to tech and media companies, pharmaceuticals and FMCG companies, often across the region or in several jurisdictions.

Everything was co-ordinated in a very good way. The lawyers also had good ideas.
Chambers Europe, 2016

Leading multinationals look to CMS for an integrated, cross-border service to meet their global needs and/or deal with global trademark portfolios, as well as specialist advice and representation in individual countries. Working with CMS gives you invaluable access to knowledge of the CEE markets and regulators, both locally and regionally. We work together with you to find the best solutions for your business.

The right brands will win the hearts and minds of your customers. The right patents will prevent others exploiting your ideas or provide a substantial barrier to market access. Copyright, know-how and designs also play a vital role. We focus on key sectors relevant to you such as life sciences and healthcare, automotive, machinery, manufacturing, consumer products, financial services, and technology, media and communications.

The overall impression of the is very positive. The team provided a lot of support and assistance.
Chambers Europe, 2016

This means you get in-depth industry knowledge as well as legal expertise for the protection of your IP. If you are involved in a dispute, CMS dedicated contentious IP experts can guide you through the litigation process.

In Poland our IP team focuses on enforcement and litigation relating to patents, trademarks, designs, and copyrights. Our experts work with Polish customs on a regular basis with regards to managing clients’ IP rights enforcement programmes.

Read more Read less
High­lights of our ex­per­i­ence in In­tel­lec­tu­al Prop­erty...

Feed

Show only
28 October 2019
CMS moves its EU trade marks and design prac­tice to...
03 Feb 20
SkyKick: Good news for brand own­ers - the CJEU's rul­ing main­tains...
Sum­mary The eagerly awaited judg­ment in the SkyKick case (C-371/18) was pub­lished on Wed­nes­day. The case relates to ques­tions re­ferred to the CJEU by the UK High Court in trade mark in­fringe­ment pro­ceed­ings...
22 August 2019
The Auto­mot­ive In­dustry Re­port 2019/20
31 Jan 20
UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
30 July 2018
The Auto­mot­ive In­dustry Re­port 2018/19
31 Jan 20
A Short Guide: Pri­or­ity En­ti­tle­ment at the EPO
Art­icle 87 EPC Pri­or­ity right (1) Any per­son who has duly filed, in or for (a) any State party to the Par­is Con­ven­tion for the Pro­tec­tion of In­dus­tri­al Prop­erty or (b) any Mem­ber of the World Trade Or­gan­iz­a­tion,...
15 November 2017
CMS con­tin­ues to in­vest in its in­tel­lec­tu­al prop­erty...
15 Jan 20
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
9 October 2017
CMS Po­land launches law com­pet­i­tion for stu­dents
20 Dec 19
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
2 August 2017
The Auto­mot­ive In­dustry Re­port 2017/18
17 Dec 19
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....